BSLN.SW Basilea (SIX) CHF57.00 after hours 13 Feb 2026: earnings 17 Feb may set tone

BSLN.SW stock trades at CHF57.00 in after-hours trade on 13 Feb 2026, a decline of -1.55% on the day as investors position ahead of Basilea Pharmaceutica AG’s earnings on 17 Feb 2026. The company reports a trailing EPS of 5.48 and a PE of 10.60, below the Healthcare sector multiple. With product sales from Cresemba and pipeline readouts for derazantinib and lisavanbulin, earnings and guidance will likely drive short-term volatility and reprice valuation.

BSLN.SW stock: after-hours price action and immediate drivers

Basilea Pharmaceutica AG (BSLN.SW) closed the regular session at CHF57.00 and is trading after hours on 13 Feb 2026. Intraday range was CHF56.90 to CHF58.40, with volume 25,418.00 versus an average volume of 37,077.00. One-day change was -0.90 CHF or -1.55%, linking price movement to position-taking ahead of the company earnings announcement on 17 Feb 2026. Market participants will watch revenue mix from Cresemba and any guidance or commentary on late-stage oncology trials.

Earnings calendar and catalysts for BSLN.SW earnings

Basilea’s next formal earnings event is scheduled for 17 Feb 2026. Key catalysts include reported revenue for Cresemba and Zevtera, R&D updates on derazantinib phase 2 programs, and any changes to commercialization guidance or licensing activity. A positive surprise on margins or clearer guidance on Derazantinib enrollment could prompt an upside re-rating; conversely, weaker product sales or extended trial timelines could pressure the stock.

Fundamental snapshot and valuation vs sector

On fundamentals BSLN.SW shows a trailing EPS of 5.48 and a reported PE of 10.60, versus the Healthcare sector average PE of 33.57. Market cap stands at CHF712983562.00 and book value per share is 8.25. Key ratios: price/earnings 10.60, price/sales 3.87, and price/book 7.04. Basilea’s free cash flow yield 9.34% and current ratio 6.32 indicate strong liquidity, while debt-to-equity at 0.94 signals modest leverage relative to peers.

Technical picture and trading signals for BSLN.SW

Technically the stock shows short-term momentum: RSI 75.56 (overbought), MACD histogram 0.15, and ADX 34.38 indicating a strong trend. The 50-day average is CHF54.44 and the 200-day average is CHF49.79 — both below the current price, supporting a near-term bullish bias. Bollinger upper band sits at CHF57.03, matching current levels and suggesting reduced upside without a catalyst. Traders should monitor volume; today’s 25,418.00 reading was below the 30-day average.

Meyka AI rating and forecast for BSLN.SW

Meyka AI rates BSLN.SW with a score out of 100: 81.50 | Grade: A | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model highlights strong profitability (ROE 70.33%), healthy cash per share 10.27, and solid free cash flow metrics.

Meyka AI’s forecast model projects a near-term monthly price of CHF63.02, a yearly projection of CHF54.32, and three-year target CHF64.26. These are model-based projections and not guarantees. Use earnings on 17 Feb 2026 as a primary catalyst to validate model assumptions.

Analyst view, risks and realistic price targets for BSLN.SW

Public analyst consensus is limited for Basilea; official price target coverage is sparse. Given current metrics we present a pragmatic range: a conservative target CHF50.00, a base-case target CHF60.00, and an optimistic target CHF70.00, with the midpoint CHF60.00. Upside depends on Cresemba sales growth and positive trial readouts. Primary risks: trial setbacks, slower-than-expected uptake in key markets, and product liability or regulatory delays.

Final Thoughts

Short-term, BSLN.SW stock at CHF57.00 on 13 Feb 2026 sits at an inflection point ahead of Basilea Pharmaceutica AG’s earnings on 17 Feb 2026. Fundamentals show attractive profitability (PE 10.60, EPS 5.48) and strong liquidity (cash per share 10.27). Technically the chart is stretched with RSI 75.56 and price above both 50- and 200-day averages, so earnings must deliver to sustain momentum. Meyka AI’s forecast model projects a monthly level of CHF63.02, implying an upside of 10.56% versus the current price of CHF57.00; forecasts are model-based projections and not guarantees. Investors should watch revenue mix, margin detail, and clinical progress in the earnings release — those items will likely determine whether the stock tests the CHF60.00–CHF70.00 range or reverts toward CHF50.00

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.